M. L. Trawick

发表

Structure analysis of (3S)(2-oxo-6-thioxo-3-piperidinyl)-phenylmethylcarbamate, C13H14N2O3S

D. Mullica, M. L. Trawick, Y. Shao, 1994 .

Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment

R. Mason, Maoping Li, M. L. Trawick, 2021, Cancers.

Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues.

T. E. Strecker, E. Hamel, M. L. Trawick, 2019, MedChemComm.

Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.

R. Mason, D. Chaplin, T. E. Strecker, 2016, MedChemComm.

A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

R. Mason, Dawen Zhao, M. L. Trawick, 2011, Integrative biology : quantitative biosciences from nano to macro.

Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.

G. Pettit, M. L. Trawick, K. Edvardsen, 2006, Bioorganic & medicinal chemistry.

Synthesis and biochemical evaluation of thiochromanone thiosemicarbazone analogues as inhibitors of cathepsin L.

D. Chaplin, M. L. Trawick, Jian-Guo Song, 2012, ACS medicinal chemistry letters.

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L.

M. Horsman, D. Chaplin, M. L. Trawick, 2012, European journal of medicinal chemistry.

Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease.

Ming Zhou, M. L. Trawick, K. Pinney, 2006, Bioorganic & medicinal chemistry letters.

Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.

D. Chaplin, B. Siim, M. L. Trawick, 2010, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy.

M. L. Trawick, John J. Hall, K. Pinney, 2008, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L.

Zhe Shi, D. Chaplin, M. L. Trawick, 2017, Bioorganic & medicinal chemistry letters.

Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

R. Mason, D. Chaplin, E. Hamel, 2013, Journal of natural products.

Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.

D. Chaplin, M. L. Trawick, Jian-Guo Song, 2013, Bioorganic & medicinal chemistry letters.

Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

E. Hamel, M. L. Trawick, R. Tanpure, 2009, Bioorganic & medicinal chemistry.

Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization.

R. Mason, D. Saha, D. Chaplin, 2019, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.

R. Mason, D. Chaplin, E. Hamel, 2016, Bioorganic & medicinal chemistry.

Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.

Zhe Shi, D. Chaplin, E. Hamel, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Ashleigh L. Barnes, M. Horsman, D. Chaplin, 2015, Bioorganic & medicinal chemistry.

Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.

D. Chaplin, G. Pettit, M. L. Trawick, 2008, Bioorganic & medicinal chemistry letters.

Regio- and stereospecific synthesis of mono-beta-d-glucuronic acid derivatives of combretastatin A-1.

D. Chaplin, B. Siim, M. L. Trawick, 2010, Journal of natural products.

Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.

D. Chaplin, G. Pettit, M. L. Trawick, 2008, Journal of natural products.

Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors †

R. Mason, Heling Zhou, M. L. Trawick, 2021, Molecules.

Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

R. Mason, D. Chaplin, Heling Zhou, 2018, MedChemComm.

Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

D. Chaplin, E. Hamel, M. L. Trawick, 2013, Bioorganic & medicinal chemistry.

Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization.

R. Mason, D. Chaplin, E. Hamel, 2015, Bioorganic & medicinal chemistry.

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Alejandro J. Ramirez, R. Mason, Zhe Shi, 2020, Journal of natural products.

Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.

D. Chaplin, M. L. Trawick, R. Tanpure, 2013, Bioorganic & medicinal chemistry.

Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.

D. Chaplin, E. Hamel, B. Siim, 2011, Journal of natural products.

An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.

D. Chaplin, E. Hamel, M. L. Trawick, 2012, MedChemComm.

Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment

R. Mason, H. Hammers, M. L. Trawick, 2022, Cancers.

The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.

R. Mason, D. Chaplin, Li Li, 2015, Cancer letters.

Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.

E. Graves, R. Mason, R. Hallac, 2015, American journal of nuclear medicine and molecular imaging.

Synthesis, characterization, and X-ray crystal structure of di-(2,4-imidazolidinedione-5-ethyl)disulfide, C10H14N4O4S2

D. Mullica, M. L. Trawick, E. Sappenfield, 1998 .

Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors

D. Chaplin, B. Siim, M. L. Trawick, 2010, Bioorganic & Medicinal Chemistry Letters.